Core Viewpoint - The company, Xinde Technology, is preparing for an IPO in Hong Kong, aiming for revenue and profit growth by 2025, despite a generally slow-growing animal health market in China and globally [1][8]. Group 1: Company Overview - Xinde Technology is a leading animal health enterprise in China, ranking third in the poultry veterinary biological products sector with a market share of 7.9% [1]. - The company has a diverse product range, including veterinary biological products, traditional Chinese veterinary medicine, chemical preparations, animal feed, and feed additives [2]. - As of September 30, 2025, Xinde Technology has nearly 300 veterinary drug production licenses, ensuring protection against major animal diseases [2]. Group 2: Financial Performance - Revenue for 2024 and the first nine months of 2025 is projected to grow by -0.3% and 25.2%, respectively, with net profit margins of 2.8% and 6.3% [1]. - The gross profit margin has shown an upward trend, reaching 49.7% in the first nine months of 2025, with vaccine products contributing significantly to this margin [5]. - The company has maintained a stable expense ratio, with total expenses ranging between 32-34% [5]. Group 3: Market Strategy - Xinde Technology's growth strategy includes three core business segments: mature business in poultry products, a growing international business, and a nurturing segment for pet and aquaculture health products [4]. - The company has entered markets in Pakistan, Egypt, and Vietnam, with plans to expand into 31 additional countries [4]. - Direct sales accounted for 67.9% of revenue in the first nine months of 2025, primarily targeting large animal farms and government institutions [4]. Group 4: Research and Development - The company invests significantly in R&D, with R&D expense ratios of 7%, 8.2%, and 7.5% from 2023 to the first nine months of 2025 [7]. - Xinde Technology holds 82 invention patents and has developed industry-leading technologies, including the first veterinary transfer factor product approved in China [7]. - The company has established four advanced manufacturing bases and 34 production lines certified under the new veterinary GMP standards [7]. Group 5: Industry Context - The global animal health market is projected to reach $51.1 billion in 2024, with a compound annual growth rate of only 4.9% over the past five years [1][6]. - The Chinese animal health market is valued at 68 billion yuan, with a compound growth rate of 6% [1][6]. - The industry faces intense competition with over 1,500 veterinary drug manufacturers in China, but Xinde Technology's focus on R&D provides a competitive edge [6].

Core Viewpoint - The company, Xinde Technology, is set to go public in Hong Kong, aiming for revenue and profit growth by 2025, despite a generally slow-growing animal health market in China and globally [1]. Group 1: Company Overview - Xinde Technology is a leading animal health enterprise in China, ranking third in the poultry veterinary biological products sector with a market share of 7.9% [1]. - The company has 20 subsidiaries, with five major contributors to its operations, including Beijing Xinde and Shandong Haili [1]. - The company reported a revenue decline of 0.3% in 2024, followed by a projected increase of 25.2% in the first nine months of 2025, with net profit margins of 2.8% and 6.3% respectively [1]. Group 2: Market and Financial Performance - The global animal health market is projected to reach $51.1 billion (approximately 352.59 billion RMB) in 2024, with a compound annual growth rate (CAGR) of only 4.9% over the past five years [1]. - The Chinese market is estimated at 68 billion RMB, with a CAGR of 6% [1]. - The company has a cash and cash equivalents balance of 137 million RMB as of September 2025 [1]. Group 3: Business Segments and Revenue Sources - Xinde Technology's product range includes veterinary biological products, traditional Chinese veterinary medicine, chemical preparations, animal feed, and feed additives [2]. - Vaccine products constitute the largest revenue share, accounting for 48.5% in 2024 and 53.8% in the first nine months of 2025 [2]. - The company has nearly 300 veterinary drug production licenses, ensuring coverage for major poultry and livestock diseases [2]. Group 4: Strategic Initiatives and Growth - The company employs a three-pronged business strategy focusing on mature, growth, and nurturing segments, with international business showing over 100% growth in the first nine months of 2025 [4]. - Xinde Technology has entered markets in Pakistan, Egypt, and Vietnam, with plans to expand into 31 countries [4]. - Direct sales accounted for 67.9% of revenue in the first nine months of 2025, indicating a strong customer base among large animal farms and government agencies [4]. Group 5: Profitability and R&D Investment - The company's gross margin has shown an upward trend, increasing from 46.3% in 2023 to 49.7% in the first nine months of 2025 [4]. - R&D expenses as a percentage of revenue were 7% in 2023, 8.2% in 2024, and 7.5% in the first nine months of 2025, with 82 patents accumulated [7]. - The company has invested 1.1 billion RMB in advanced manufacturing capacity, establishing four production bases and 34 production lines certified under the new veterinary drug GMP [8]. Group 6: Industry Challenges and Outlook - The animal health industry faces intense competition with over 1,500 manufacturers in China, leading to limited growth prospects [7]. - Despite the industry's challenges, Xinde Technology's strong fundamentals and ongoing international expansion may attract value investors post-IPO [9].